HomeCompareSUFF vs ABBV

SUFF vs ABBV: Dividend Comparison 2026

SUFF yields 1000000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SUFF wins by $4.7683925249533696e+36M in total portfolio value
10 years
SUFF
SUFF
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full SUFF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — SUFF vs ABBV

📍 SUFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSUFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SUFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SUFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SUFF
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, SUFF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SUFF + ABBV for your $10,000?

SUFF: 50%ABBV: 50%
100% ABBV50/50100% SUFF
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SUFF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SUFF buys
0
ABBV buys
0
No recent congressional trades found for SUFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSUFFABBV
Forward yield1000000.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.7683925249533696e+36M$104.7K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$25,725.73
Total dividends collected$4.7683311610149396e+36M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SUFF vs ABBV ($10,000, DRIP)

YearSUFF PortfolioSUFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,559$438.51+$100.00MSUFF
2$934,786,450,701$934,679,439,252.34$13,494$640.86+$934786.44MSUFF
3$8,165,787,108,578,292$8,164,786,887,076,042.00$15,951$945.97+$8165787108.56MSUFF
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$19,152$1,413.89+$66665884190957.63MSUFF
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$23,443$2,146.38+$508662171058048128.00MSUFF
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$29,391$3,321.96+$3.62723524842849e+21MSUFF
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$37,948$5,265.87+$2.417368115915061e+25MSUFF
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$50,795$8,596.74+$1.5056740286145463e+29MSUFF
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$71,034$14,549.41+$8.764771002818475e+32MSUFF
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$104,715$25,725.73+$4.7683925249533696e+36MSUFF

SUFF vs ABBV: Complete Analysis 2026

SUFFStock

Ophir Resources Co. designs, manufactures, and sells apparel and training gear products related to mixed martial arts (MMA) worldwide. It provides apparel products, including T-shirts, fight shorts, and caps for men and women. The company sells its products through in-house representatives, authorized distributors, and authorized retailers, as well as through the Internet. The company was formerly known as Suffer and changed its name to Ophir Resources Co. in January 2013. Ophir Resources Co. was founded in 2004 and is based in Las Vegas, Nevada.

Full SUFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SUFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SUFF vs SCHDSUFF vs JEPISUFF vs OSUFF vs KOSUFF vs MAINSUFF vs JNJSUFF vs MRKSUFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.